Background and purpose: The a7 nicotinic acetylcholine receptor (nAChR) has attracted considerable interest as a target for cognitive enhancement in schizophrenia and Alzheimer's Disease. However, most recently described a7 agonists are derived from the quinuclidine structural class. Alternatively, the present study identifies tilorone as a novel a7-selective agonist and characterizes analogues developed from this lead. Experimental approach: Activity and selectivity were determined from rat brain a7 and a4b2 nAChR binding, recombinant nAChR activation, and native a7 nAChR mediated stimulation of ERK1/2 phosphorylation in PC12 cells. Key results: Tilorone bound a7 nAChR (IC 50 110 nM) with high selectivity relative to a4b2 (IC 50 70 000 nM), activated human a7 nAChR with an EC 50 value of 2.5 mM and maximal response of 67% relative to acetylcholine, and showed little agonist effect at human a3b4 or a4b2 nAChRs. However, the rat a7 nAChR maximal response was only 34%. Lead optimization led to 2-(5-methyl-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl)-xanthen-9-one (A-844606) with improved binding (a7 IC 50 11 nM, a4b2 IC 50 430 000 nM) and activity at both human and rat a7 nAChR (EC 50 s 1.4 and 2.2 mM and apparent efficacies 61 and 63%, respectively). These compounds also activated native a7 nAChR, stimulating ERK1/2 phosphorylation in PC12 cells. Conclusions and implications: Tilorone, known as an interferon inducer, is a selective a7 nAChR agonist, suggesting utility of the fluorenone pharmacophore for the development of a7 nAChR selective agonists. Whether a7 stimulation mediates interferon induction, or whether interferon induction may influence the potential anti-inflammatory properties of a7 nAChR agonists remains to be elucidated.
Introduction
The past 15 years have witnessed the cloning of 17 different nicotinic acetylcholine receptor (nAChR) subunits, demonstrating nAChR expression not only in muscle and autonomic ganglia but also in sensory ganglia, throughout the central nervous system, and in a variety of non-neuronal cells (Jensen et al., 2005; Gahring and Rogers, 2006) . Over half of these subunits are expressed in brain, and often coexpressed in the same cells. As nAChRs are pentameric, there is potential for a considerable variety of functionally and pharmacologically distinct nAChRs. Among the more prominent nAChR in brain are the a4b2 heteromeric and a7 homomeric subtypes, both of which have been implicated in sensory gating, cognitive processes and other physiological functions (Martin et al., 2004; D'Andrea and Nagle, 2006) . Additionally, there is increasing evidence that a7 nAChR may play important roles in non-neuronal processes, such as angiogenesis (Heeschen et al., 2002) and inflammation (Tracey, 2005; Ulloa, 2005) .
To address these targets, subtype-selective compounds continue to be developed, particularly to avoid adverse effects mediated by a3-containing nAChR in autonomic ganglia. The a7 nAChR is a target of considerable interest, due to the critical disease processes in which it is implicated (for example, schizophrenia and Alzheimer's disease) and the idea that novel selective agonists could be developed given the pharmacological distinction exemplified by the selective antagonists a-bungarotoxin and the alkaloid methyllycaconitine (MLA).
The first compound advanced as an a7-selective agonist was GTS-21, also known as DMXBA (Briggs et al., 1995; Kem, 2000; Papke et al., 2004) . However, the selectivity of GTS-21 is context dependent. Although it was found to activate rat a7 nAChR selectively, it also binds a4b2 nAChR and it was found to elicit a low maximal response at recombinant human a7 nAChR in vitro (Briggs et al., 1995; Meyer et al., 1998) . Whether the a4b2 ligand properties contribute towards or detract from the physiological effects of is not yet clear. Additionally, active metabolites of GTS-21 have been identified, and may contribute effects in vivo .
Recently, more efficacious a7 nAChR-selective ligands have been found, such as AR-R 17779 (Van Kampen et al., 2004) , PNU-282987 (Bodnar et al., 2005) , PHA-543613 (Wishka et al., 2006) , SSR-180711 (Biton et al., 2007; Pichat et al., 2007) , ABBF (Boess et al., 2007) and others (Tatsumi et al., 2006) . However, except for GTS-21 and SSR-180711, all these compounds share a quinuclidine pharmacophore.
A seemingly unrelated compound, tilorone, has been known as an interferon inducer since 1970 Mayer and Krueger, 1970) . We found that tilorone is a selective a7 nAChR ligand. Other tricyclic compounds have been found to inhibit a4b2 and other b2-containing nAChR at micromolar concentrations (Connolly et al., 1992) . Surprisingly, however, tilorone acted as a highly selective agonist for a7 nAChR. Thus, tilorone appeared to represent a novel structural scaffold for discovery of a7-selective agonists. Here, we describe the in vitro functional properties of tilorone and three related analogues.
Materials and methods
Rat a7 nAChR binding Binding to rat a7 nAChR was measured by [ 3 H]MLA displacement as described by Davies et al. (1999 ) was used and nonspecific binding was determined in the presence of 10 mM (À)-nicotine.
Human and rat recombinant a7 nAChR functional evaluation Female Xenopus laevis frogs obtained from Nasco (Fort Atkinson, WI, USA) and from Blades Biological Ltd. (Cowden, Edenbridge, Kent, UK) were maintained and treated using standard protocols approved by Abbott's Institutional Animal Care and Use Committee. The preparation and maintenance of X. laevis oocytes and their injection with cDNA or cRNA prepared by standard techniques followed procedures similar to those described previously (Briggs et al., 1995; Trumbull et al., 2003) . Oocytes were injected within 24 h of their preparation and were used 2-7 days after injection.
a7 nAChR responses were measured by two-electrode voltage clamp (À60 mV) at room temperature in OR-2 solution (pH 7.4) containing 90 mM NaCl, 2.5 mM KCl, 2.5 mM CaCl 2 , 1.0 mM MgCl 2 , 5 mM Na-HEPES buffer and 0.5 mM atropine to block endogenous muscarinic receptors. Agonists were applied using the robotic Gilson pipettor of the POETs apparatus (Trumbull et al., 2003) and responses were measured as the compound-induced peak (maximal) inward current relative to the baseline-holding current and normalized to the acetylcholine (ACh) response determined in the same oocyte. In each oocyte, 10 mM ACh, which elicited a maximal a7 nAChR response (Briggs and McKenna, 1998; Briggs et al., 1999) , was applied before and after test compound to test response stability and for the purpose of normalizing test compound's response to the maximal ACh response. Typically, ACh was applied several times initially to ensure stability, followed by two applications of test compound, followed by two applications of ACh, followed by two applications of test compound, etc. The intervals between applications were 5 min, which were sufficient for full recovery of the ACh response, or longer. High concentrations of some compounds can produce a prolonged afterinhibition of the nAChR response, perhaps due to slow washout or channel block. This could be detected as a reduction in the control ACh response. In such instances, the interval between applications was increased or control ACh applications were added, thereby increasing the test compound washout duration. Responses affected by prolonged after-inhibition or other forms of instability reflected by ACh controls were discarded. Otherwise, responses to test compound were normalized to an average of the 10 mM ACh responses determined before and after test compound. Concentration-response parameters were determined using the nonlinear curve fitting in Graphpad Prism and the built-in variable slope sigmoidal curve (Hill equation); fitting parameters were not constrained except that the bottom of the curve was set equal to 0.
Rat native a7 nAChR signalling via phospho-ERK Activation of native a7 nAChR signalling in rat PC12 cells was assessed by stimulation of ERK1/2 phosphorylation (Gubbins et al., 2006) . Briefly, PC12 cells obtained from American Type Culture Collection (Manassas, VA, USA) were cultured in poly-D-lysine coated 96-well plates containing Ham's F12K supplemented with 15% horse serum (heat inactivated), 2.5% fetal bovine serum and 2 mM glutamine. At 24 h before the experiment, culture medium was replaced a7 nAChR and tilorone analogues CA Briggs et al with non-supplemented F12K to reduce the basal level of ERK phosphorylation. Cells were transferred to Hank's balanced salt solution (HBSS) with or without nAChR antagonist for a 60 min preincubation (37 1C), then 3 mM PNU-120596 (Hurst et al., 2005) to reduce a7 nAChR desensitization, followed 10 min later by nAChR agonist and a final 7-min incubation in a final volume of 100 ml. Activity was terminated by transferring the incubation plate to ice, aspirating the medium and lysing the cells on ice for 15 min with 5 ml Insect Cell Lysis Buffer containing 1% sodium deoxycholate, 0.1% sodium dodecylsulphate, 1 mM sodium orthovanadate, 1% protease inhibitor cocktail and 100 U ml À1 benzonase. Samples were stored at À80 1C prior to assay of total ERK and phospho-ERK by western blot using fluorescent antibodies. Secondary antibodies were fluorescently labelled with Alexafluor-680 or IRDye800. Signals were measured by Li-Cor Odyssey Infrared Imaging System.
Non-a7 recombinant nAChR functional evaluation
The effects of compounds on non-a7 nAChR were measured as described previously (Grønlien et al., 2007) using fluorescence light-imaging plate reader (FLIPR), Ca 2 þ -sensitive fluorescent probes and human neuroblastoma IMR-32 or HEK293 cell lines expressing recombinant human a3* or a4* nAChR. Responses were normalized to the response to 100 mM (À)-nicotine determined in the same 96-well plate. Additionally, the ability of tilorone and A-844606 to activate human a4b2 nAChR was tested by whole-cell patch clamp using standard techniques and the same HEK293 cell line as used in FLIPR. The cells were maintained in polystyrene culture flasks (175 mm 2 ) with Dulbecco's modified Eagle's medium plus Glutamax supplemented with 10% fetal bovine serum, 100 mg ml À1 zeocin and 0.5 mg ml
À1
geneticin and a humidified atmosphere of 5% CO 2 in air at 37 1C. For transfer, cells were rinsed with 4 ml phosphatebuffered saline, incubated for 2 min in 1 ml of TrypLE Select, resuspended in 25 ml culture medium with trituration, and plated onto 12 mm diameter coverslips coated with poly-Dlysine and mouse laminin. Patch-clamp recordings were obtained 1-2 days after plating with standard borosilicate glass electrodes (2-5 MO) and HEKA EPC-9 amplifier. The extracellular solution contained 130 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 2 mM MgCl 2 , 10 mM Na-HEPES buffer (pH 7.4) and 0.5 mM atropine. The intracellular (pipette) solution contained 130 mM KCl, 5 mM NaCl, 2 mM K-EGTA, 2 mM MgCl 2 and 10 mM K-HEPES (pH 7.4). Serial resistance was o10 MO and was uncompensated.
Compounds were applied using theta-tube liquid filament and Burleigh PZ-150M piezo-electric device for position switching. For applying different compounds to the same cell, the solution in one barrel of the theta tube could be changed using a manifold valve (Type C25Z-3180; Valco Instruments Co. Inc., Schenkon, Switzerland). Agonist was applied for 2 s with 180 s between applications. 
Materials

Results
Binding to a7 and a4b2 nAChR was determined in rat brain membranes by displacement of radioligands selective for the respective nAChR subtypes. Tilorone displaced [ While the relatively large size of tilorone compared with other a7 nAChR agonists initially suggested that it may be an antagonist, in fact, it was found to be a highly selective agonist. Tilorone activated human a7 nAChR expressed in oocytes with an EC 50 value of 2.5 mM and maximal response of 67% relative to 10 mM ACh, as shown in Figure 1 and Table 1 . Tilorone activated rat a7 nAChR with similar potency (EC 50 ¼ 0.94 mM), but with a smaller maximal response (34%) compared with human a7 nAChR ( Figure 1 and Table 1) .
Among the analogues developed through lead optimization were 2,7-bis(hexahydropyrrolo [3,4-c] pyrrol-2(1H)-yl)-9H-fluoren-9-one (A-746050) and the 'one-armed' analogues exemplified by 2-amino-7-(hexahydropyrrolo [3,4-c] pyrrol-2(1H)-yl)-9H-fluoren-9-one (A-795723) and 2-(5-methyl-hexahydro-pyrrolo [3,4-c] pyrrol-2-yl)-xanthen-9-one (A-844606). Structures and concentration-response data are shown in Figure 1 and Table 1. A-746050 bound a7 nAChR with an IC 50 value of 0.87 nM (0.47-1.6 nM CI, n ¼ 3) compared with a4b2 nAChR where the IC 50 value was 6000-fold higher (IC 50 ¼ 9.3 mM, 6.2-14 mM CI, n ¼ 6). A-746050 functioned as a rat a7 nAChR agonist with an EC 50 value of 0.22 mM and maximal response of 59%. However, A-746050 elicited a somewhat smaller maximal response (41%) at human a7 nAChR.
Reducing one of the diazabicyclo [3.3.0] octane arms to an amino group in A-795723 (Figure 1 ) had little impact on binding, as the a7 nAChR IC 50 was 1.4 nM (0.70-2.9 nM CI, n ¼ 5) and selectivity against a4b2 nAChR was maintained (IC 50 ¼ 26 mM, 21-31 mM CI, n ¼ 3). This compound functioned as an a7 agonist with low EC 50 (0.3 mM), comparable potencies at rat and human a7 nAChR, but low maximal response (28-33%) ( Table 1) . a7 nAChR and tilorone analogues CA Briggs et al
Further development of these analogues included modification of the fluorenone pharmacophore, leading to the compound A-844606 (Figure 1) . A-844606 had somewhat lower affinity for rat brain a7 nAChR (IC 50 ¼ 11 nM, 4-29 nM CI, n ¼ 4) compared with the above compounds, but was about 30-fold more potent than tilorone and retained selectivity against a4b2 nAChR (IC 50 430 mM, n ¼ 4). Further, as an a7 agonist, A-844606 was potent and efficacious, without the apparent rat/human species selectivity evident in tilorone (Table 1) .
Functional selectivity of A-844606 across other nAChR subtypes was evaluated using Ca 2 þ imaging in neuroblastoma and transfected cell lines. At concentrations at or above the a7 nAChR EC 50 value, tilorone and A-844606 (3 mM) had Concentration-response parameters were determined by nonlinear fitting of the Hill equation to the values depicted in Figure 1 . Data are shown as mean (95% confidence interval) for EC 50 and mean ± s.e.mean for Hill coefficient and maximal response relative to ACh (10 mM). The values for n are the number of determinations per data point. Table 1 . Also shown are sample responses to 100 mM tilorone and 10 mM ACh from one oocyte (a) and 100 mM A-844606 and 10 mM ACh from another oocyte (d). In each case, the response to ACh is the larger one. Scale bars represent 500 nA and 500 ms for all.
little agonist effect on human nAChR other than a7, as shown for a4b2 expressed in HEK293 (Figure 2a ) and the native a3* expressed by IMR-32 cells (Figure 2b ). Only at 100 mM was there an apparent small effect of A-844606 as an agonist. However, both compounds did weakly inhibit human a4b2 and a3* responses to nicotine (Figures 2c and d) . The selectivity of these compounds for activation of human a7 versus a4b2 nAChR was consistent with their selectivity for a7 versus a4b2 binding in rat brain membranes. For further confirmation, responses to tilorone (10 mM), A-844606 (10 mM) and ACh (100 mM) were measured in the human a4b2 HEK293 cell line using patch-clamp electrophysiology. In four cells responding to ACh, neither tilorone nor A-844606 elicited a measurable response (Figure 3) .
To evaluate the abilities of tilorone and A-844606 to activate rat native a7 nAChR and associated signalling cascades, stimulation of ERK1/2 phosphorylation in PC12 cells was determined. As shown in Figure 4a , both tilorone and A-844606 stimulated ERK1/2 phosphorylation, with EC 50 values of 0.59 and 0.047 mM, respectively. Compared with a7 nAChR responses measured electrophysiologically in oocytes, these EC 50 values are lower and responses are larger because of the inclusion of an a7-selective positive allosteric modulator in the ERK1/2 assay. A-844606 was more potent than tilorone or nicotine and was similar in potency to a reference a7 nAChR agonist, PNU-282987, in this assay (Gubbins et al., 2006) .
Blockade experiments with MLA suggested that the increase in ERK1/2 phosphorylation was due to stimulation of a7 nAChR, at least in part (Figures 4b and c) . A-844606 (1 mM) increased phospho-ERK1/2 to 95 ± 5% of the response to 1 mM PNU-282987 (n ¼ 3). This was reduced to 58±5% in the presence of 10 nM MLA, and 8 ± 0.9% in the presence of 50 nM MLA. Likewise, tilorone (10 mM) increased phospho-ERK1/2 to 83±12% (n ¼ 3) and this was reduced to 11±11% in 10 nM MLA, and À1.0 ± 1.7% in 50 nM MLA. While MLA appeared somewhat less potent against A-844606 than against tilorone, it is not clear whether that is due to a non-a7 effect of A-844606 or to the larger response of rat a7 nAChR to A-844606 than to tilorone. In either case, the results suggest that A-844606 is a potent agonist at rat native a7 nAChR as well as recombinant human and rat a7 nAChR. d) were measured using a human a4b2 nAChR stably-transfected HEK293 cell line and in the human neuroblastoma IMR-32 using fluorescence light-imaging plate reader (FLIPR) Ca 2 þ imaging. Data from the agonist assay (a, b) (n ¼ 7-11 per data point) were normalized to the response to 100 mM nicotine determined in each plate. A-844606 elicited a small apparent increase in fluorescence at 100 mM, whereas tilorone elicited no significant response. The compounds were also evaluated as antagonists of the response to 100 mM nicotine (c, d). Tilorone (c) inhibited a4b2 nAChR with an IC 50 value of 19 mM (8.7-42 mM CI, n ¼ 3) and IMR-32 a3* nAChR with an IC 50 value of 0.45 mM (0.31-0.66 mM CI, n ¼ 6). A-844606 (d) inhibited a4b2 nAChR with an IC 50 value of 4.0 mM (3.0-5.3 mM CI, n ¼ 9) and IMR-32 a3* nAChR with an IC 50 value of 0.52 mM (0.41-0.65 mM CI, n ¼ 10).
Discussion
Screening of an in-house compound library identified tilorone as a novel ligand that bound and activated a7 nAChR. Surprisingly, tilorone has been known for over 30 years as an orally active interferon inducer (Levin and Albrecht, 1981) . To our knowledge, never before has tilorone been evaluated as a ligand for a neurotransmitter receptor. The mechanism by which tilorone acts as an interferon inducer is not clear, and there is no direct evidence to implicate a7 nAChR in the process. However, from a structural perspective, tilorone was a novel a7 nAChR ligand. Lead optimization explored the structure-activity relationship around tilorone, leading to the identification of potent and selective analogues, as for example A-844606.
Further studies explored the selectivity and function of tilorone and related compounds at recombinant and native nAChR in vitro. Tilorone and analogues including A-844606 functioned as selective a7 nAChR agonists with little or no agonist activity at recombinant a4b2, a3b2 and a3b4 nAChR or at a3* nAChR expressed natively in IMR-32 neuroblastoma cells as measured by FLIPR. Failure to activate a4b2 was confirmed by patch-clamp recordings. Nicotine and numerous other compounds demonstrating potent binding to a4b2 sites in rat brain do activate human a4b2 nAChR and IMR-32 nAChR in the FLIPR assay (Frost et al., 2006; Bunnelle et al., 2007; Ji et al., 2007a, b) . Rather, micromolar concentrations of tilorone and A-844606 inhibited a4b2 and IMR-32 nAChR, perhaps similar to the inhibition of b2-containing nAChR by other tricyclics (Connolly et al., 1992) . Thus, interaction of these compounds with recombinant human a4b2 nAChR and with native IMR-32 nAChR was characterized by inhibition of the response to nicotine rather than activation.
At a7 nAChR, the agonist potency of A-844606 was about 30-fold higher than that of (À)-nicotine and similar to that of epibatidine. Furthermore, tilorone and A-844606 were active as agonists in the native a7 nAChR ERK1/2 signalling expressed by PC12 cells as well as at recombinant a7 nAChR expressed in Xenopus oocytes and measured electrophysiologically. Thus, these compounds represent potent, efficacious and highly selective a7 nAChR agonists that could be used as tool compounds for comparison versus a7-selective agonists from other structural classes.
Tilorone displayed relatively lower maximal responses at rat compared with human a7 nAChR, limiting its potential utility in rodent behavioural models. Additionally, tilorone may have a number of nonspecific adverse effects, such as binding to glycosaminoglycans and DNA intercalation, at a7 nAChR and tilorone analogues CA Briggs et al high concentrations (Bispinck et al., 1998; Alcaro et al., 2004) . Such effects are thought to be promoted by the amphiphilic structure of tilorone, with a central negative region and positive charge at each end of the molecule contributed by the tertiary amines protonated at physiological pH. Thus, A-844606 represents an optimized analogue as it is not only more potent than tilorone but also displayed no species selectivity between rat and human a7 nAChR activation and, with its one amine 'arm', is presumed to have reduced affinity for nonspecific sites.
Localization of a7 nAChR in hippocampus and cortex (Hogg et al., 2003; Alkondon and Albuquerque, 2004) , high levels of a7 nAChR expression during brain development (Adams et al., 2002; Falk et al., 2003; Tribollet et al., 2004) and apparent neuroprotective properties of a7 nAChR stimulation in vitro (Belluardo et al., 2000; O'Neill et al., 2002) led to the idea that a7 nAChR may be involved in cognitive processing and perhaps synapse formation or stabilization. In a7 nAChR knockout animals, effects on behavioural performance and hippocampal anatomy were subtle, as revealed from initial studies (Orr-Urtreger et al., 1997). However, more recent studies have pointed to performance deficits in the a7 nAChR knockout animals (Young et al., 2006) . In wild-type animals, nicotine and other nAChR agonists have been found to enhance cognitive performance, an effect that may involve a4b2 as well as a7 activation (Levin et al., 2002; Newhouse et al., 2004; Mazurov et al., 2006) . GTS-21 also enhances cognitive performance, but this compound binds to a4b2 as well as a7 nAChR (de Fiebre et al., 1995; Briggs et al., 1997; Kem et al., 2004; Olincy et al., 2006) . Pharmacological evidence to support the idea that a7 nAChR activation alone may be sufficient to enhance cognitive performance has come largely from the quinuclidine class of compounds. Thus, it will be of significant interest to determine whether a7 agonists from other structural classes are able to replicate the cognitive enhancement and other positive behavioural effects of the foregoing compounds.
